|
1）Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factor VIII and IX. Haemophilia. 2006; 12: 15-22
|
|
|
|
2）Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood. 2006; 108: 3739-45
|
|
|
|
|
3）Astermark J, Oldenburg J, Pavlova A, et al. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2006; 107: 3167-72
|
|
|
|
|
|
4）Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009; 360: 1618-27
|
|
|
|
|
|
5）Matzinger P. The danger model: a renewed sense of self. Science. 2002; 296: 301-5
|
|
|
|
|
|
6）Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunol-ogical danger signals can reduce FVIII inhibitor development. Haemophilia. 2010; 16: 256-62
|
|
|
|
|
|
7）Andre S, Meslier Y, Dimitrov JD, et al. A cellular viewpoint of anti-FVIII immune response in hemophilia A. Clin Rev Allergy Immunol. 2009; 37: 105-13
|
|
|
|
|
|
8）van Helden PM, Kaijen PH, Fijnvandraat K, et al. Factor VIII-specific memory B cells in patients with hemophilia A. J Thromb Haemost. 2007; 5: 2306-8
|
|
|
|
|
|
9）Reding MY, Wu H, Krampf M, et al. Sensitization of CD4＋T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost. 2000; 84: 643-52
|
|
|
|
|
|
10）Kallas A, Kuuse S, Maimets T, et al. Naturally occurring CD4＋CD25＋ cells in modulating immune response to administered coagulation factor VIII in factor VIII-deficient mice. Haemophilia. 2011; 17: 143-51
|
|
|
|
|
|
11）Hausl C, Ahmad RU, Sasgary M, et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood. 2005; 106: 3415-22
|
|
|
|
|
|
12）田中一郎，天野景裕，瀧 正志，他. インヒビター保有先天性血友病患者に対する止血療法ガイドライン. 血栓止血誌. 2008; 19: 520-39
|
|
|
|
|
13）Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007; 109: 546-51
|
|
|
|
|
|
14）Ogiwara K, Nogami K, Tanaka I, et al. Tissue-factor pathway inhibitor causes unresponsiveness to activated prothrombin complex concentrates for hemophilia A patients with inhibitors. Blood. 2010; Abstract for ASH meeting
|
|
|
|
|
|
15）Hay CR, DiMichele DM. International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119: 1335-44
|
|
|
|
|
|
16）Moss J, Rosholm A, Lauren A. Safety and pharmacokinetics of a glycoPEGylated recom-binant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost. 2011; 9: 1368-74
|
|
|
|
|
|
17）de Paula EV, Kavakli K, Mahlangu J, et al. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a random-ized controlled trial. J Thromb Haemost. 2012; 10: 81-9
|
|
|
|
|
|
18）Tomokiyo K, Nakatomi Y, Araki T, et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang. 2003; 85: 290-9
|
|
|
|
|
|
19）Prasad S, Lillicrap D, Labelle A, et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood. 2008; 111: 672-9
|
|
|
|
|
|
20）Franchini M, Mengoli C, Lippi G, et al. Immune tolerance with rituximab in congenital haemo-philia with inhibitors: a systematic literature review based on individual patients analysis. Haemophilia. 2008; 14: 903-12
|
|
|
|
|
|
21）Qian J, Collins M, Sharpe AH, et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood. 2000; 95: 1324-9
|
|
|
|
|
|
22）Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood. 2011; 97: 2759-7
|
|
|
|
|
|
23）Salooja N, Kemball-Cook G, Tuddenham EG, et al. Use of a non-depleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX. Br J Haematol. 2002; 118: 839-42
|
|
|
|
|
|
24）Waters B, Qadura M, Burnett B, et al. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4＋CD25＋-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood. 2009; 113: 193-203
|
|
|
|
|
|
25）Dasgupta S, Repesse Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007; 109: 610-2
|
|
|
|
|
|
26）Parker ET, Healey JF, Barrow RT, et al. Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood. 2004; 104: 704-10
|
|
|
|
|
|
27）Purohit VS, Ramani K, Sarkar R, et al. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem. 2005; 280: 17593-600
|
|
|
|
|
|
28）Madoiwa S, Yamauchi T, Hakamata Y, et al. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. J Thromb Haemost. 2004; 2: 754-62
|
|
|
|
|
|
29）Madoiwa S, Yamauchi T, Kobayashi E, et al. Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A. J Thromb Haemost. 2009; 7: 811-24
|
|
|
|
|
|
30）Matsui H, Shibata M, Brown B, et al. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3＋ T regulatory cells. Blood. 2009; 114: 677-85
|
|
|
|
|
|
31）Rawle FE, Pratt KP, Labelle A, et al. Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain. J Thromb Haemost. 2006; 4: 2172-9
|
|
|
|
|
|
32）Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood. 2005; 105: 4865-70
|
|
|
|
|
|
33）Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011; 365: 2357-65
|
|
|
|
|